Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs.
Rodriguez Antolin
A
A
Department of Urology, Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense de Madrid, Spain.
Morales
J M
JM
Andrés
A
A
Fernández Aparicio
T
T
Díaz González
R
R
Pamplona
M
M
Alvarez
E
E
D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use*; D010410:Penile Erection / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D006435:Renal Dialysis; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D010208:Papaverine; D000527:Alprostadil